Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s303. https://doi.org/10.25251/skin.8.supp.303